深圳信立泰药业股份有限公司 关于向香港联交所递交H股发行上市申请并刊发申请资料的公告

Group 1 - The company, Shenzhen Xinlitai Pharmaceutical Co., Ltd., submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange on February 12, 2026 [1][2] - The application materials were published on the Hong Kong Stock Exchange website and are subject to updates and revisions as required by the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1][2] - If the issuance and listing are implemented, the target investors will be limited to qualified foreign investors and domestic qualified investors authorized to conduct overseas securities investments according to Chinese laws and regulations [1][2] Group 2 - The announcement serves to inform domestic investors about the issuance and listing, and does not constitute an offer or invitation to purchase the H-shares [2] - The issuance and listing are subject to approvals from relevant government agencies and regulatory bodies, including the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange, indicating uncertainty in the process [2] - The company will fulfill its information disclosure obligations in accordance with the progress of the matter [2]